Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Optimal Treatments for Severe Malaria and the Threat Posed by Artemisinin Resistance.

Jones S, Hodel EM, Sharma R, Kay K, Hastings IM.

J Infect Dis. 2019 Apr 8;219(8):1243-1253. doi: 10.1093/infdis/jiy649.

2.

Modelling the impact of insecticide-based control interventions on the evolution of insecticide resistance and disease transmission.

Barbosa S, Kay K, Chitnis N, Hastings IM.

Parasit Vectors. 2018 Aug 28;11(1):482. doi: 10.1186/s13071-018-3025-z.

3.

Insecticide resistance evolution with mixtures and sequences: a model-based explanation.

South A, Hastings IM.

Malar J. 2018 Feb 15;17(1):80. doi: 10.1186/s12936-018-2203-y.

4.

A Two-Locus Model of the Evolution of Insecticide Resistance to Inform and Optimise Public Health Insecticide Deployment Strategies.

Levick B, South A, Hastings IM.

PLoS Comput Biol. 2017 Jan 17;13(1):e1005327. doi: 10.1371/journal.pcbi.1005327. eCollection 2017 Jan.

5.

Quantifying the pharmacology of antimalarial drug combination therapy.

Hastings IM, Hodel EM, Kay K.

Sci Rep. 2016 Sep 8;6:32762. doi: 10.1038/srep32762.

6.

The Importance of Scientific Debate in the Identification, Containment, and Control of Artemisinin Resistance.

Hastings IM, Kay K, Hodel EM.

Clin Infect Dis. 2016 Dec 1;63(11):1527-1528. Epub 2016 Aug 23. No abstract available.

PMID:
27558565
7.
8.

Incorporating Stage-Specific Drug Action into Pharmacological Modeling of Antimalarial Drug Treatment.

Hodel EM, Kay K, Hastings IM.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2747-56. doi: 10.1128/AAC.01172-15. Print 2016 May.

9.

Reply to "Parasite Strain, Host Immunity, and Circulating Blood Cells with Dead Parasites: Why Predicting Malaria Parasite Clearance Is Not a Simple Task".

Hastings IM, Kay K, Hodel EM.

Antimicrob Agents Chemother. 2016 Jan 29;60(2):1173-4. doi: 10.1128/AAC.02570-15. Print 2016 Feb. No abstract available.

10.

Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.

Kay K, Hodel EM, Hastings IM.

Antimicrob Agents Chemother. 2015 Oct;59(10):6419-27. doi: 10.1128/AAC.00482-15. Epub 2015 Aug 3.

11.

How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?

Hastings IM, Kay K, Hodel EM.

Antimicrob Agents Chemother. 2015 Oct;59(10):6428-36. doi: 10.1128/AAC.00481-15. Epub 2015 Aug 3.

12.

Measuring windows of selection for anti-malarial drug treatments.

Kay K, Hastings IM.

Malar J. 2015 Jul 31;14:292. doi: 10.1186/s12936-015-0810-4.

13.

Mathematical models of human african trypanosomiasis epidemiology.

Rock KS, Stone CM, Hastings IM, Keeling MJ, Torr SJ, Chitnis N.

Adv Parasitol. 2015 Mar;87:53-133. doi: 10.1016/bs.apar.2014.12.003. Epub 2015 Feb 11. Review.

PMID:
25765194
14.

Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.

Kay K, Hodel EM, Hastings IM.

Antimicrob Agents Chemother. 2014 Oct;58(10):5643-9. doi: 10.1128/AAC.02777-14. Epub 2014 Jun 30.

15.

Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.

Hodel EM, Kay K, Hayes DJ, Terlouw DJ, Hastings IM.

Malar J. 2014 Apr 7;13:138. doi: 10.1186/1475-2875-13-138.

16.

Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough?

Hastings IM, Hodel EM.

Malar J. 2014 Feb 20;13:62. doi: 10.1186/1475-2875-13-62. Review.

17.
18.

Entomological indices of malaria transmission in Chikhwawa district, Southern Malawi.

Mzilahowa T, Hastings IM, Molyneux ME, McCall PJ.

Malar J. 2012 Nov 21;11:380. doi: 10.1186/1475-2875-11-380.

19.
20.

Prediction of hospital mortality from admission laboratory data and patient age: a simple model.

Asadollahi K, Hastings IM, Gill GV, Beeching NJ.

Emerg Med Australas. 2011 Jun;23(3):354-63. doi: 10.1111/j.1742-6723.2011.01410.x. Epub 2011 Apr 28.

PMID:
21668723
21.

Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Winter K, Hastings IM.

Antimicrob Agents Chemother. 2011 Jul;55(7):3380-92. doi: 10.1128/AAC.01712-10. Epub 2011 May 2.

22.

ogaraK: a population genetics simulator for malaria.

Antao T, Hastings IM.

Bioinformatics. 2011 May 1;27(9):1335-6. doi: 10.1093/bioinformatics/btr139. Epub 2011 Mar 16.

PMID:
21414984
23.

Leukocytosis as an alarming sign for mortality in patients hospitalized in general wards.

Asadollahi K, Hastings IM, Beeching NJ, Gill GV, Asadollahi P.

Iran J Med Sci. 2011 Mar;36(1):45-9.

24.

Why we should effectively treat malaria.

Hastings IM.

Trends Parasitol. 2011 Feb;27(2):51-2. doi: 10.1016/j.pt.2010.10.003. No abstract available.

PMID:
21281927
25.

Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria.

Antao T, Hastings IM.

Proc Biol Sci. 2011 Jun 7;278(1712):1705-12. doi: 10.1098/rspb.2010.1907. Epub 2010 Nov 17.

26.

A comparison of methods to detect and quantify the markers of antimalarial drug resistance.

Hastings IM, Nsanzabana C, Smith TA.

Am J Trop Med Hyg. 2010 Sep;83(3):489-95. doi: 10.4269/ajtmh.2010.10-0072.

27.

Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance.

Marfurt J, Smith TA, Hastings IM, Müller I, Sie A, Oa O, Baisor M, Reeder JC, Beck HP, Genton B.

Malar J. 2010 Jan 7;9:8. doi: 10.1186/1475-2875-9-8.

28.

Quantifying the evolution and impact of antimalarial drug resistance: drug use, spread of resistance, and drug failure over a 12-year period in Papua New Guinea.

Nsanzabana C, Hastings IM, Marfurt J, Müller I, Baea K, Rare L, Schapira A, Felger I, Betschart B, Smith TA, Beck HP, Genton B.

J Infect Dis. 2010 Feb 1;201(3):435-43. doi: 10.1086/649784.

PMID:
20047502
29.

Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies.

Babiker HA, Hastings IM, Swedberg G.

Expert Rev Anti Infect Ther. 2009 Jun;7(5):581-93. doi: 10.1586/eri.09.29. Review.

PMID:
19485798
30.

Probability of emergence of antimalarial resistance in different stages of the parasite life cycle.

Pongtavornpinyo W, Hastings IM, Dondorp A, White LJ, Maude RJ, Saralamba S, Day NP, White NJ, Boni MF.

Evol Appl. 2009 Feb;2(1):52-61.

31.

Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.

Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ.

Malar J. 2008 Nov 2;7:229. doi: 10.1186/1475-2875-7-229.

32.

MalHaploFreq: a computer programme for estimating malaria haplotype frequencies from blood samples.

Hastings IM, Smith TA.

Malar J. 2008 Jul 15;7:130. doi: 10.1186/1475-2875-7-130.

33.

Climate prediction of El Niño malaria epidemics in north-west Tanzania.

Jones AE, Wort UU, Morse AP, Hastings IM, Gagnon AS.

Malar J. 2007 Dec 6;6:162.

34.

Molecular markers as indicators of antimalarial drug failure rates.

Hastings IM.

Trop Med Int Health. 2007 Nov;12(11):1298-301. Epub 2007 Oct 22.

35.

The anatomy of a malaria disaster: drug policy choice and mortality in African children.

Hastings IM, Korenromp EL, Bloland PB.

Lancet Infect Dis. 2007 Nov;7(11):739-48. Epub 2007 Sep 19. Review.

PMID:
17884732
36.

"Sexual" population structure and genetics of the malaria agent P. falciparum.

Mzilahowa T, McCall PJ, Hastings IM.

PLoS One. 2007 Jul 18;2(7):e613.

37.

Laboratory risk factors for hospital mortality in acutely admitted patients.

Asadollahi K, Hastings IM, Beeching NJ, Gill GV.

QJM. 2007 Aug;100(8):501-7. Epub 2007 Jul 3.

PMID:
17609227
38.

Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance.

Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R.

Lancet Infect Dis. 2007 Feb;7(2):136-44. Review.

PMID:
17251084
39.

Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'.

Hastings IM, Lalloo DG, Khoo SH.

AIDS. 2007 Jan 11;21(2):258-9; author reply 259-60. No abstract available.

PMID:
17197825
40.

No room for complacency on drug resistance in Africa.

Hastings IM, Lalloo DG, Khoo SH.

Nature. 2006 Nov 2;444(7115):31. No abstract available.

PMID:
17080063
41.

PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX.

Bray PG, Mungthin M, Hastings IM, Biagini GA, Saidu DK, Lakshmanan V, Johnson DJ, Hughes RH, Stocks PA, O'Neill PM, Fidock DA, Warhurst DC, Ward SA.

Mol Microbiol. 2006 Oct;62(1):238-51. Epub 2006 Aug 31.

42.
43.

Will ART rollout in Africa drive an epidemic of drug resistant HIV?

Hastings IM, Lalloo D, Khoo SH.

AIDS. 2006 Jun 12;20(9):1354-6; author reply 1356-7. No abstract available.

PMID:
16816578
44.

Population genetics: XYZW as nature's language of love?

Hastings IM.

Heredity (Edinb). 2006 Apr;96(4):278-9. No abstract available.

45.

Complex dynamics and stability of resistance to antimalarial drugs.

Hastings IM.

Parasitology. 2006 May;132(Pt 5):615-24. Epub 2006 Jan 23.

PMID:
16426485
46.

Tolerance is the key to understanding antimalarial drug resistance.

Hastings IM, Watkins WM.

Trends Parasitol. 2006 Feb;22(2):71-7. Epub 2006 Jan 10. Review.

PMID:
16406706
47.

Antibiotic chemotherapy of onchocerciasis: in a bovine model, killing of adult parasites requires a sustained depletion of endosymbiotic bacteria (Wolbachia species).

Gilbert J, Nfon CK, Makepeace BL, Njongmeta LM, Hastings IM, Pfarr KM, Renz A, Tanya VN, Trees AJ.

J Infect Dis. 2005 Oct 15;192(8):1483-93. Epub 2005 Sep 14.

PMID:
16170768
48.

Coartem (artemether-lumefantrine) in Africa: the beginning of the end?

Hastings IM, Ward SA.

J Infect Dis. 2005 Oct 1;192(7):1303-4; author reply 1304-5. No abstract available.

PMID:
16136476
49.

Malaria and irrigated crops, Accra, Ghana.

Klinkenberg E, McCall PJ, Hastings IM, Wilson MD, Amerasinghe FP, Donnelly MJ.

Emerg Infect Dis. 2005 Aug;11(8):1290-3.

50.

The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance.

Hastings IM, Donnelly MJ.

Drug Resist Updat. 2005 Feb-Apr;8(1-2):43-50. Epub 2005 Apr 18. Review.

PMID:
15939341

Supplemental Content

Loading ...
Support Center